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Abstract
Background:  Outcomes collected in randomized clinical trials are observations of random
variables that should be independent and identically distributed. However, in some trials, the
patients are randomized more than once thus violating both of these assumptions. The probability
of an event is not always the same when a patient is re-randomized; there is probably a non-zero
covariance coming from observations on the same patient. This is of particular importance to the
meta-analysts.
Methods: We developed a method to estimate the relative error in the risk differences with and
without re-randomization of the patients. The relative error can be estimated by an expression
depending on the percentage of the patients who were re-randomized, multipliers (how many
times more likely it is to repeat an event) for the probability of reoccurrences, and the ratio of the
total events reported and the initial number of patients entering the trial.
Results: We illustrate our methods using two randomized trials testing growth factors in febrile
neutropenia. We showed that under some circumstances the relative error of taking into account
re-randomized patients was sufficiently small to allow using the results in the meta-analysis. Our
findings indicate that if the study in question is of similar size to other studies included in the meta-
analysis, the error introduced by re-randomization will only minimally affect meta-analytic summary
point estimate.
We also show that in our model the risk ratio remains constant during the re-randomization, and
therefore, if a meta-analyst is concerned about the effect of re-randomization on the meta-analysis,
one way to sidestep the issue and still obtain reliable results is to use risk ratio as the measure of
interest.
Conclusion: Our method should be helpful in the understanding of the results of clinical trials and
particularly helpful to the meta-analysts to assess if re-randomized patient data can be used in their
analyses.
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Background
Statistical tests performed to evaluate differences in the
outcomes collected in randomized clinical trials (RCTs)
are based on the assumption that all the data come from
random variables that are independent of each other.
However, in some trials, the patients are randomized
more than once, usually twice. Investigators often pool
these events and report data for all randomized patient
episodes instead of episode per patient. Therefore, the
independence assumption can be violated.
Concerns about the re-randomization of patients on
febrile neutropenia trials have been raised by some
authors [1] due to a possible violation of the principle of
independency. However, this practice is accepted by the
Immunocompromised host society as a valid one [2] and
has been used in some of the trials performed in neutro-
penic patients.
We have recently encountered this problem during our
conduct of meta-analysis (MA) on the role of colony-stim-
ulating factors in the treatment of febrile neutropenia [3]
where two out of the 12 trials reported analysis according
to febrile neutropenia episodes instead of episodes per
patients. In this paper, we address the issue whether the
combined (pooled) risk difference (RD) after re-randomi-




Assuming that once an event (FN episode) occurred in a
patient the probability of another occurrence is likely to
be different from its initial value, we introduce a parame-
ter d measuring this change:
Previously, Chouaid et al. [4] provided the data on the
probability of FN after each randomization. Data were
available from 39 patients, of which seven had an event;
six of these patients were re-randomized and four of them
had another occurrence of event.
Thus, accordingly an estimate for d can be obtained by
. To avoid messy notation, we will
omit the 'hat' from the estimates of these parameters. This
indicates that the patient who develops an FN episode
after first cycle will have about 3.71 times higher likeli-
hood of development of FN in the second chemotherapy
cycle. Note that our calculations also work for values d < 1.
On the other hand, the patients who did not experience
an episode of FN are usually less likely to experience it
after re-randomization. The probability of an FN episode
in a patient who didn't experience an episode of FN in the
first round is c times smaller (or larger, if c > 1) in the sec-
ond round of randomization. In this example,
.
To illustrate this study, we present a chronological tree
diagram in figure 1. Although this is the only study we
were able to find which provided data on re-randomiza-
tion in both arms, it likely represents a typical scenario for
the assumptions used in our model.
Results
Calculations
Assume that N patients in a clinical control trial are being
randomized (for the first time) in such way that NC
patients are randomized into the control group and NA
patients are selected into the experimental (alternate)
group. In order to simplify our calculations, we have set
NA ≈  NC ≈  N / 2. The percentage of people who were re-
randomized (randomized for the second time) is x. After
re-randomization, the total number of events is reported
as ECT for the control group and EAT for the experimental
group. The total number of events reported is given by ET
= EAT + ECT.
Consider the following two variables:
EA – the number of events in experimental group in the
initial randomization;
EC – the number of events in control group in the initial
randomization;
These two numbers are the most important in our calcu-
lations. We can then estimate the initial risk difference
, compare it to the reported numbers and
observe the relative error. In the following paragraphs, we
will work toward estimating these two variables.
Chouaid et al. study Figure 1
Chouaid et al. study
d =
The probability of second occurence of an event after re- -randomization
The probability of an event before re-random mization
.
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E = EA + EC – the total number of events in the initial
randomization;
NE = N - E – the number of patients without an event in
the initial randomization;
 – the risk at which events occurred in the exper-
imental group;
 – the risk at which events occurred in the con-
trol group;
 – the risk differ-
ence for the initial randomization;
Assuming that re-randomization is approximately evenly
divided (if not, we can change the fraction 1/2 with appro-
priate value), the re-randomized control group and re-
randomized experimental group will have the following
sizes:
 – the size of experimental re-
randomized group;
 – the size of control re-rand-
omized group;
In Figure 2, we summarize the relationship between these
variables in a general case. In order to do both, the analy-
sis of difference in outcome between the experimental
group and control group, as well as the analysis of
repeated randomizations, all of the entries identified in
the figure must be determined.
Having in mind that the reoccurrence of an event is d
times more likely (or less likely if d < 1) if the patient
comes from the E – group (patients with events), and c
times less likely (or more likely if c > 1) if it comes from
NE-group (patients without events), and that the events
occur at the initial risks pA and pC for the experimental and
control groups, respectively, we have:
 – the number of re-rand-
omization events in the experimental group;
 – the number of re-rand-
omization events in the control group;
Therefore, the risk difference of the re-randomization
alone, can be calculated as
The overall risk difference for both randomizations, the
initial one and the re-randomization, can then be calcu-
lated as
or replacing the formula above
The relative error between the overall risk difference and
the risk difference resulting from considering the patients
only from the initial randomization is then estimated by
the expression
However, the fraction   is usually not reported, and
therefore has to be estimated. We will estimate this via the
average risk 
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Adding these two equations, we get the quadratic equa-
tion in terms of p  , which
can be solved as:
, where ET =
EAT + ECT. Replacing this resulting estimate into the rela-
tive difference equation above, leads to
which after some simplifying becomes our main formula:
Therefore, the relative error of the reported risk difference
and the actual risk difference before re-randomization can
be estimated by the expression depending on x – the per-
centage of the patients who were re-randomized, d and c
– multipliers for the probability of reoccurrence of the
event, and the ratio   of the total events reported and
the initial number of patients entering the trial.
An Excel file performing all of these calculations and
allowing the readers to enter their own data is enclosed as
an Additional File 1.
Figure 3 describes our method graphically. The vertical
axis is x – the percent of the patients who were re-rand-
omized. The horizontal axis is d – the multiplier by which
the probability of an event changed after an initial occur-
rence of an event. Figure helps to determine under which
circumstances the error in risk difference is less than 5%.
The curves represent 5% relative error level curves for
Tree diagram showing the relationships between the variables in the re-randomization process Figure 2
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different values of the ratio   of the total events
reported and the initial number of patients entering the
trial. The values of the ratio   are indicated at the top of
the graph.
For a chosen value of the ratio  : if a point (d, x) is
between the two level curves with identical value – the rel-
ative error of the risk differences is less than 5%; otherwise
– the relative error of the risk differences is more than 5%.
Risk ratio
The overall risk ratio after the re-randomization can be
defined as  , since we
assumed that NA ≈  (N / 2) ≈  NC and .
Then, using the definitions of pA and pC, we obtain the fol-
lowing equation:
which is exactly the risk ratio of the initial randomization.
Therefore, the overall risk ratio after the re-randomization
is equal to the initial risk ratio after the first randomiza-
tion. Interestingly enough, the risk ratio is not affected by
the re-randomization.
Odds ratio
The overall odds ratio after the re-randomization can be 
defined as  , which can 
The 0.05 level curves for the relative difference between the risk difference before and after the re-randomization Figure 3
The 0.05 level curves for the relative difference between the risk difference before and after the re-randomiza-
tion. We assume that c = 0.40 in this figure. The horizontal axis represents d – the multiplier for the probability of reoccur-
rence of the event after the re-randomization; The vertical axis represents x – the percentage of the patients who were re-
randomized; The curves represent 0.05 relative error level curves for different values of the ratio   of the total events 
reported and the initial number of patients entering the trial. The values of the ratio   are indicated at the top of the graph. 
For a chosen value of the ratio  : if a point (d, x) is between the two level curves with identical value (and color) – the rela-
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be simplified as 
On the other hand, the odds ratio from the first randomi-
zation alone can be expressed as  . Using 
the formulas 
 and 
, we get the expression 
. The relative 
difference between the odds ratio before the re-randomi-
zation and the overall odds ratio can therefore be 
expressed as
Data from CSF trials
To illustrate our method, we will use examples from two
papers that studied use of CSFs in the treatment of chem-
otherapy-related febrile neutropenia (FN) and reported
the number of patients who were hospitalized and
remained in the hospital longer than 10 days [5,6]. In
both of these trials some of the patients were re-rand-
omized after first FN episode (hospitalization).
Mitchell et al[5] studied 112 patients in the first randomi-
zation for the effect of G-CSF in FN. Seventy-four of these
patients were re-randomized (x = 66.07%). From a graph
in their paper we deduced that 18% and 20% of the
patients on GCSF and placebo, respectively, remained in
the hospital longer than 10 days. This translates into 17
and 18 events in these two treatment arms
. From the graph
in the Figure 3, and assuming [4] that d = 3.71 and c =
0.40, we estimate the relative difference between the
reported risk difference evaluated for all the patients, and
the risk difference resulting from considering the patients
only in the first initial randomization to be only 0.70%.
The point corresponding to this example is marked by the
purple circle in the Figure 3. In our case, the point is safely
between the two identical   level curves (the first
and the third curve from the right) indicating that the rel-
ative error is smaller than 5%.
Anaissie et al. [6] studied effect of GM-CSF on FN in 92
patients, of which 15.9% were re-randomized (x = 0.159).
Overall, 18 and 26 patients in GM-CSF and placebo arm
remained in the hospital after 10 days
. The difference is now
8.23%. The point corresponding to this example is indi-
cated by the blue square in the Figure 3. Note that this
time the point is not between two  -level curves,
indicating that the relative error is larger than 5%.
The odds ratio for this data also changes from OR = 0.554
before the re-randomization to the overall value after re-
randomization OR = 0.535, a change of 3.49%.
Estimating the risks in the initial randomization
Meta-analysts would also like to know at what risks the
events occur in the experimental and control groups
before any re-randomization is performed. For example,
while in the first example the relative difference between
the reported risk difference and the risk difference before
the re-randomization was not considerable; in the second
example we found a considerable difference.
Some meta-analysts might prefer to use the risks of the
events from the initial randomization, i.e., before any re-
randomization was performed. In this section we will try
to estimate these risks.
By estimating first the average risk 
 and solving 
the equations above for p, we have 
, where
ET = EAT + ECT. Using this parameter, the formulas for pA 
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and
Using these estimates, we can get the estimates of EA and
EC – the number of events in the initial randomization in
experimental and control arms of the trial, respectively.
If the number of patients in each arm of the trial in the ini-
tial randomization is given, the events are estimated as EA
= pA·NA and EC = pC·NC. If the only number we have is the
total number of patients entering the initial randomiza-
tion, N, the events must be estimated more crudely as
 and  .
In the case of Anaissie et al. example, we obtain the fol-
lowing estimates for the number of events: EA = 14 and EC
= 21, and since we are not given the number of patients in
each arm, we have to estimate each to 46. Therefore, the
numbers we could use for a meta-analysis from this par-
ticular trial would be
Experimental  14 / 46
Control  21 / 46
Discussion
Our method has been developed using the example of
febrile neutropenia (FN) in which the patients who once
developed FN are considered to be at increased risk for
subsequent event [7]. We assume that it is not possible to
reliably predict which patients will develop the event of
interest from the outset of the trial, but that once the event
occurred the risk for subsequent event will be higher in
those patients who had developed the first event. Because
of this we adopted the values of d > 1 and c < 1. However,
it is conceivable that biology of the process may differ in
different circumstances. A meta-analyst is well advised to
work with the content-specific experts to address this
issue. The same formulas can be used to reflect any com-
bination of the values for d and c parameters, except when
c = d.
A reader should note that in our model the parameters c
and d work in "conditional probability" framework, i.e., it
represents a multiplicative rather than additive approach
to asses the effect of previous occurrence of the event on
the next one. This makes sense from purely clinical point
of view.
Error analysis
A natural question to ask at this point is "What is the
extent of error in the estimation of the parameters c and d
in these formulas, and in particular, in the formula (1.1)."
We first attempted to determine confidence intervals for
the parameters c  and  d. Unfortunately, since the
proportions on top and bottom of the formulas for evalu-
ation of c and d are obviously dependent random varia-
bles, none of the classical examples for evaluation of a
confidence interval of a ratio of two proportions can be
applied in this case. For example, Sutton et al [8] recom-
mend that a confidence interval for a ratio of two risks
 can be calculated using the formula
, where
. However, this formula, as well as
most other formulas, are derived from Taylor's expansion
of a transformation of random variables, and depend on
the assumption that the ratios a / b and c / d are independ-
ent (have zero covariance). In our case this assumption
can not be applied.
To determine this effect, we used the example of Anaissie
et al. [6] and created Table 1.
The top row of Table 1 represents the estimate of the
parameter c as it varies from 0 to 2, while the leftmost col-
umn indicates value of the estimate of the parameter d as
it varies from 1 to 15. The numbers in the table show the
difference between the real relative difference from for-
mula (1.1) and the relative difference calculated with
these alternate values for c and d. The value .000 (boxed)
in the table corresponds to the difference from the RD cal-
culated with c = 0.4 and d = 3.7 in our example (Anaissie
et al. [6]). However, if we assume that c = 0.7, and that d
= 9.4, the value of RD (circled) will be larger by 21.6%,
i.e., instead of 8.23%, the value of relative Risk Difference
given by the formula (1.1) will be 29.83%. In this case we
estimated that the original number of patients who under-
went first randomization was 12/46 in experimental
group, and 17/46 in the control group, respectively (see
above). Note that the while some variation exists, the rel-
ative risk difference is not extraordinarily sensitive to the
variation in the parameters c and d.
Conclusion
In general, it is considered that meta-analyses represent
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effectiveness of health care interventions. However, relia-
bility of meta-analyses depends on the validity of under-
lying methods used to combine data from the individual
studies. One of the key assumptions for the valid MA is
the independence of the data being analyzed. As illus-
trated here, in practice this assumption is often violated.
The question for meta-analysts then becomes under
which circumstances data can still be properly analyzed
even if the independence axiom was violated. In the case
of FN, for example, Immunocompromised Host Society
issued a guideline in which they considered it acceptable
to have multiple randomization of the same patients and
reintroduce fully recovered patients into clinical trials
[2,9]. However, we believe that the answer regarding the
acceptability of re-randomized data is not a simple cate-
gorical "yes or no" answer, but it will depend on the
amount of error introduced into calculation. If the relative
error of risk differences in the results with and without re-
randomization is considered small, then such calculations
can be safely accepted by meta-analysts. On the other
hand, if such an error is considered large, then the analysts
should not use the re-randomized data. Instead, the esti-
mates of initial randomization from the method illus-
trated in the previous section should be used.
It is very intriguing that if the summary effect measure
selected is the risk ratio, under the assumptions of our
model there is no difference in the final outcome before
and after the re-randomization. Therefore, if a meta-ana-
lyst is concerned about the effect of re-randomization on
the meta-analysis, one way to sidestep the issue and still
obtain reliable results is to use risk ratio as the measure of
interest.
In the examples illustrated in this paper, we showed over-
all risk difference, RD (after second randomization) and
RD after first randomization in Mitchell et al. [5] trial dif-
fered by relative value of 0.7%. In the case of the trial by
Anaissie et al. [6] this difference was 8.23%. It is conceiv-
able that this large relative error (of 8.23%) may affect the
results of meta-analysis. Figures 4 and 5 show results of
meta-analysis with and without re-randomized data.
In this particular example – change in the input for the
meta-analysis did not change the outcome and only mar-
ginally changed the pooled risk difference from -9% to -
8%. In general, the effect of a given error on the results of
meta-analysis can be approximated by multiplying the
weight of a given study by the estimate of its relative error.
In our example, weight was ~8% and relative error was
also ~8% resulting in the change of the summary point
estimate in meta-analysis less than 1%. Even when the rel-
ative error is high as 29.83% (see above), the summary
point estimate would change only by 2.3%. However,
should this study have contributed to the meta-analysis
with the weight of 40%, the overall change in the sum-
mary point estimate would be about 12% (0.4 × 0.3 =
0.12). In general, however, it appears that if the study in
question is of small size relative to the rest of the studies
included in the meta-analysis, the error introduced by re-
randomization will only minimally affect meta-analytic
summary point estimate.
Although we developed our method to help with meta-
analyses, it should be stressed that our method is also
relevant to the analysis of the original trials, and may help
assess impact of re-randomization on the results of the
Table 1: Error analysis using Anaissie et al. data
≈  c
≈  d 0.0 0.1 0.2 0.3 0.4 0.7 0.9 1.2 1.5 1.7 2.0
1.0 -.286 -.272 -.259 -.245 -.232 -.197 -.162 -.128 -.096 -.064 .033
1.7 -.198 -.186 -.175 -.163 -.152 -.122 -.093 -.064 -.036 -.009 .018
2.4 -.131 -.121 -.111 -.101 -.091 -.065 -.039 -.014 .011 .035 .059
3.0 -.077 -.068 -.059 -.050 -.041 -.018 .005 .028 .050 .072 .093
3.7 -.032 -.024 -.016 -.008 .021 .042 .063 .083 .103 .123
5.6 .062 .069 .075 .082 .089 .106 .123 .140 .156 .173 .189
7.5 .131 .136 .142 .147 .153 .168 .182 .196 .211 .225 .238
9.4 .183 .188 .193 .198 .203 .229 .241 .254 .266 .278
11.2 .226 .231 .235 .239 .244 .255 .267 .278 .289 .300 .311
13.1 .262 .266 .270 .274 .278 .288 .299 .309 .319 .329 .339
15.0 .293 .296 .300 .303 .307 .317 .326 .335 .345 .354 .363
 .000
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trial. We strongly suggest that meta-analysts always com-
pare overall results of their meta-analysis to results based
on first randomizations only, as a general control of the
reliability of the meta-analysis. In order to make that pos-
sible researchers conducting randomized clinical trials
would have to report a much more detailed information
on their methodology, specifying the numbers of patients
being re-randomized, experiencing only one occurrence
of an event, experiencing two occurrences of an event, or
dropped out of the study.
We believe that the method provided in this paper repre-
sents a valuable contribution to the improvement of inter-
pretation of results of clinical trials and in particular their
use in meta-analysis. Although the development of this
method was stimulated by a concrete problem in the field
of febrile neutropenia, practice of re-randomization is
used in other areas of medicine such as testing of treat-
ments for epilepsy, recurrent headaches and anti-emetics
in cancer chemotherapy.
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